Nuron Biotech, Inc. has selected the Merck BioManufacturing Network in the UK to manufacture large-scale GMP clinical supplies of NU100 and to provide process validation leading to long-term commercial operations. NU100, entering Phase III development, is a recombinant human interferon beta compound being developed for the treatment of multiple sclerosis (MS). The manufacturing process uses PreEMT, a new large-scale pressure refold technology, which has been installed at the Billingham, UK site....